 | • レポートコード：MRC-IM30190 • 出版社/出版日：IMARC / 2022年10月 • レポート形態：英文、PDF、141ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥374,850 (USD2,499) | ▷ お問い合わせ |
| Enterprisewide | ￥674,850 (USD4,499) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| IMARC社の調査レポートによると、世界の血液悪性腫瘍市場規模は2021年に501億ドルに達しました。今後、2027年には912億ドルになり、2022年から2022年の間に年平均10.6％成長すると予測しています。本調査レポートでは、血液悪性腫瘍の世界市場について調査・分析を行い、序論、調査範囲・手法、エグゼクティブサマリー、イントロダクション、種類別（白血病、リンパ腫、多発性骨髄腫、その他）分析、治療別（化学療法、放射線治療、免疫治療、幹細胞移植、その他）分析、エンドユーザー別（病院、診断センター、研究センター、その他）分析、地域別（北米、アジア、欧州、中南米、中東・アフリカ）分析、SWOT分析（強み・弱み・機会・脅威）、バリューチェーン分析、ファイブフォース分析、価格分析、競争状況などを掲載しています。なお、企業情報には、AbbVie Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc, Novartis AG, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceutical Company Limited.などが含まれています。 ・序論 ・調査範囲・手法 ・エグゼクティブサマリー ・イントロダクション ・世界の血液悪性腫瘍市場規模：種類別 - 白血病の市場規模 - リンパ腫の市場規模 - 多発性骨髄腫の市場規模 - その他種類の市場規模 ・世界の血液悪性腫瘍市場規模：治療別 - 化学療法の市場規模 - 放射線治療の市場規模 - 免疫治療の市場規模 - 幹細胞移植の市場規模 - その他治療の市場規模 ・世界の血液悪性腫瘍市場規模：エンドユーザー別 - 病院における市場規模 - 診断センターにおける市場規模 - 研究センターにおける市場規模 - その他エンドユーザーにおける市場規模 ・世界の血液悪性腫瘍市場規模：地域別 - 北米の血液悪性腫瘍市場規模 - アジアの血液悪性腫瘍市場規模 - 欧州の血液悪性腫瘍市場規模 - 中南米の血液悪性腫瘍市場規模 - 中東・アフリカの血液悪性腫瘍市場規模 ・SWOT分析（強み・弱み・機会・脅威） ・バリューチェーン分析 ・ファイブフォース分析 ・価格分析 ・競争状況 |
The global hematologic malignancies market size reached US$ 50.1 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 91.2 Billion by 2027, exhibiting a growth rate (CAGR) of 10.6% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Hematologic malignancies, such as lymphoma, leukemia, and multiple myeloma, are cancers of blood-producing cells. These cells comprise platelets for wound clotting, red blood cells (RBCs) to carry oxygen, and white blood cells (WBCs) for immune protection, which originate from hematopoietic stem and progenitor cells in the bone marrow. Hematologic malignancies can be diagnosed using tests like microscopy, cytogenetics, immunophenotyping, flow cytometry, fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), and gene expression profiling. Nowadays, several drugs, including antitumor antibiotics, histone deacetylase inhibitors, and Janus kinase (JAK) inhibitors, are available around the world for treatment based on diagnostic tests.
Hematologic Malignancies Market Trends:
The incidence of acute myeloid leukemia (AML) is relatively higher among the geriatric population. This, in confluence with the increasing life expectancy, represents one of the key factors catalyzing the demand for hematologic malignancies drugs across the globe. Besides this, with advances in immunohistochemistry (IHC), hematologic malignancies can be diagnosed accurately by exposing tissue samples to various antibodies directed against cell molecules and antigens. This, in turn, is strengthening the growth of the market. Moreover, the rising awareness about early diagnosis, along with improving diagnostic modalities, is contributing to market growth. Apart from this, surgical therapy is available for tissue diagnosis and treatment of lymphoma complications, such as perforation, obstruction, and stricture. This, in confluence with the launch of several novel therapies and multiple label expansions of premium-priced agents, such as CAR T-cell therapies and brexucabtagene autoleuce, is propelling the market growth. Furthermore, ongoing clinical research studies to introduce advanced drugs for patients with advanced hematologic malignancies are anticipated to drive the market in the coming years.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global hematologic malignancies market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, therapy and end user.
Breakup by Type:
Leukemia
Lymphoma
Multiple Myeloma
Others
Breakup by Therapy:
Chemotherapy
Radiotherapy
Immunotherapy
Stem Cell Transplantation
Others
Breakup by End User:
Hospitals
Diagnostics Centers
Research Centers
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc, Novartis AG, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceutical Company Limited.
Key Questions Answered in This Report:
How has the global hematologic malignancies market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global hematologic malignancies market?
What are the key regional markets?
What is the breakup of the market based on the type?
What is the breakup of the market based on the therapy?
What is the breakup of the market based on the end user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global hematologic malignancies market and who are the key players?
What is the degree of competition in the industry?
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Hematologic Malignancies Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Type
6.1 Leukemia
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Lymphoma
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Multiple Myeloma
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Others
6.4.1 Market Trends
6.4.2 Market Forecast
7 Market Breakup by Therapy
7.1 Chemotherapy
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Radiotherapy
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Immunotherapy
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Stem Cell Transplantation
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Others
7.5.1 Market Trends
7.5.2 Market Forecast
8 Market Breakup by End User
8.1 Hospitals
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Diagnostics Centers
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Research Centers
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Others
8.4.1 Market Trends
8.4.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 AbbVie Inc.
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 AstraZeneca plc
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 Bristol-Myers Squibb Company
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.3.4 SWOT Analysis
14.3.4 Eli Lilly and Company
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.4.4 SWOT Analysis
14.3.5 F. Hoffmann-La Roche Ltd
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.6 GlaxoSmithKline plc
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.6.4 SWOT Analysis
14.3.7 Johnson & Johnson
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.7.4 SWOT Analysis
14.3.8 Merck & Co. Inc
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.8.4 SWOT Analysis
14.3.9 Novartis AG
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.9.3 Financials
14.3.9.4 SWOT Analysis
14.3.10 Pfizer Inc.
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.10.3 Financials
14.3.10.4 SWOT Analysis
14.3.11 Sanofi S.A.
14.3.11.1 Company Overview
14.3.11.2 Product Portfolio
14.3.11.3 Financials
14.3.11.4 SWOT Analysis
14.3.12 Takeda Pharmaceutical Company Limited
14.3.12.1 Company Overview
14.3.12.2 Product Portfolio
14.3.12.3 Financials
14.3.12.4 SWOT Analysis
Figure 2: Global: Hematologic Malignancies Market: Sales Value (in Billion US$), 2016-2021
Figure 3: Global: Hematologic Malignancies Market Forecast: Sales Value (in Billion US$), 2022-2027
Figure 4: Global: Hematologic Malignancies Market: Breakup by Type (in %), 2021
Figure 5: Global: Hematologic Malignancies Market: Breakup by Therapy (in %), 2021
Figure 6: Global: Hematologic Malignancies Market: Breakup by End User (in %), 2021
Figure 7: Global: Hematologic Malignancies Market: Breakup by Region (in %), 2021
Figure 8: Global: Hematologic Malignancies (Leukemia) Market: Sales Value (in Million US$), 2016 & 2021
Figure 9: Global: Hematologic Malignancies (Leukemia) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 10: Global: Hematologic Malignancies (Lymphoma) Market: Sales Value (in Million US$), 2016 & 2021
Figure 11: Global: Hematologic Malignancies (Lymphoma) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 12: Global: Hematologic Malignancies (Multiple Myeloma) Market: Sales Value (in Million US$), 2016 & 2021
Figure 13: Global: Hematologic Malignancies (Multiple Myeloma) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 14: Global: Hematologic Malignancies (Other Types) Market: Sales Value (in Million US$), 2016 & 2021
Figure 15: Global: Hematologic Malignancies (Other Types) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 16: Global: Hematologic Malignancies (Chemotherapy) Market: Sales Value (in Million US$), 2016 & 2021
Figure 17: Global: Hematologic Malignancies (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 18: Global: Hematologic Malignancies (Radiotherapy) Market: Sales Value (in Million US$), 2016 & 2021
Figure 19: Global: Hematologic Malignancies (Radiotherapy) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 20: Global: Hematologic Malignancies (Immunotherapy) Market: Sales Value (in Million US$), 2016 & 2021
Figure 21: Global: Hematologic Malignancies (Immunotherapy) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 22: Global: Hematologic Malignancies (Stem Cell Transplantation) Market: Sales Value (in Million US$), 2016 & 2021
Figure 23: Global: Hematologic Malignancies (Stem Cell Transplantation) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 24: Global: Hematologic Malignancies (Other Therapies) Market: Sales Value (in Million US$), 2016 & 2021
Figure 25: Global: Hematologic Malignancies (Other Therapies) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 26: Global: Hematologic Malignancies (Hospitals) Market: Sales Value (in Million US$), 2016 & 2021
Figure 27: Global: Hematologic Malignancies (Hospitals) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 28: Global: Hematologic Malignancies (Diagnostics Centers) Market: Sales Value (in Million US$), 2016 & 2021
Figure 29: Global: Hematologic Malignancies (Diagnostics Centers) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 30: Global: Hematologic Malignancies (Research Centers) Market: Sales Value (in Million US$), 2016 & 2021
Figure 31: Global: Hematologic Malignancies (Research Centers) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 32: Global: Hematologic Malignancies (Other End Users) Market: Sales Value (in Million US$), 2016 & 2021
Figure 33: Global: Hematologic Malignancies (Other End Users) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 34: North America: Hematologic Malignancies Market: Sales Value (in Million US$), 2016 & 2021
Figure 35: North America: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 36: United States: Hematologic Malignancies Market: Sales Value (in Million US$), 2016 & 2021
Figure 37: United States: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 38: Canada: Hematologic Malignancies Market: Sales Value (in Million US$), 2016 & 2021
Figure 39: Canada: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 40: Asia-Pacific: Hematologic Malignancies Market: Sales Value (in Million US$), 2016 & 2021
Figure 41: Asia-Pacific: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 42: China: Hematologic Malignancies Market: Sales Value (in Million US$), 2016 & 2021
Figure 43: China: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 44: Japan: Hematologic Malignancies Market: Sales Value (in Million US$), 2016 & 2021
Figure 45: Japan: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 46: India: Hematologic Malignancies Market: Sales Value (in Million US$), 2016 & 2021
Figure 47: India: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 48: South Korea: Hematologic Malignancies Market: Sales Value (in Million US$), 2016 & 2021
Figure 49: South Korea: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 50: Australia: Hematologic Malignancies Market: Sales Value (in Million US$), 2016 & 2021
Figure 51: Australia: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 52: Indonesia: Hematologic Malignancies Market: Sales Value (in Million US$), 2016 & 2021
Figure 53: Indonesia: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 54: Others: Hematologic Malignancies Market: Sales Value (in Million US$), 2016 & 2021
Figure 55: Others: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 56: Europe: Hematologic Malignancies Market: Sales Value (in Million US$), 2016 & 2021
Figure 57: Europe: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 58: Germany: Hematologic Malignancies Market: Sales Value (in Million US$), 2016 & 2021
Figure 59: Germany: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 60: France: Hematologic Malignancies Market: Sales Value (in Million US$), 2016 & 2021
Figure 61: France: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 62: United Kingdom: Hematologic Malignancies Market: Sales Value (in Million US$), 2016 & 2021
Figure 63: United Kingdom: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 64: Italy: Hematologic Malignancies Market: Sales Value (in Million US$), 2016 & 2021
Figure 65: Italy: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 66: Spain: Hematologic Malignancies Market: Sales Value (in Million US$), 2016 & 2021
Figure 67: Spain: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 68: Russia: Hematologic Malignancies Market: Sales Value (in Million US$), 2016 & 2021
Figure 69: Russia: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 70: Others: Hematologic Malignancies Market: Sales Value (in Million US$), 2016 & 2021
Figure 71: Others: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 72: Latin America: Hematologic Malignancies Market: Sales Value (in Million US$), 2016 & 2021
Figure 73: Latin America: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 74: Brazil: Hematologic Malignancies Market: Sales Value (in Million US$), 2016 & 2021
Figure 75: Brazil: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 76: Mexico: Hematologic Malignancies Market: Sales Value (in Million US$), 2016 & 2021
Figure 77: Mexico: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 78: Others: Hematologic Malignancies Market: Sales Value (in Million US$), 2016 & 2021
Figure 79: Others: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 80: Middle East and Africa: Hematologic Malignancies Market: Sales Value (in Million US$), 2016 & 2021
Figure 81: Middle East and Africa: Hematologic Malignancies Market: Breakup by Country (in %), 2021
Figure 82: Middle East and Africa: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 83: Global: Hematologic Malignancies Industry: SWOT Analysis
Figure 84: Global: Hematologic Malignancies Industry: Value Chain Analysis
Figure 85: Global: Hematologic Malignancies Industry: Porter's Five Forces Analysis